Xenetic Biosciences, Inc. XBIO
Xenetic Biosciences, Inc. (Nasdaq: XBIO) is an oncology drug developer. Its lead program, systemic DNase (IV rhDNase I), is in Pre-clinical for adjunctive therapy for pancreatic ductal adenocarcinoma, colorectal and other locally advanced or metastatic solid tumors. Its next catalyst on record is NucleoCapture: Pivotal study in SLE expected to start Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NucleoCapture — Pivotal study in SLE expected to start Q4 2026. (Q4 2026). 18 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| systemic DNase (IV rhDNase I) | PDAC, CRC and other solid tumors (targets neutrophil extracellular traps) | protein/peptide | Pre-clinical |
| PolyXen (legacy platform) | partnered drug-delivery platform; royalties received | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.